WO2000012067A1 - Nouvelle forme saline pharmaceutique - Google Patents

Nouvelle forme saline pharmaceutique Download PDF

Info

Publication number
WO2000012067A1
WO2000012067A1 PCT/US1999/019575 US9919575W WO0012067A1 WO 2000012067 A1 WO2000012067 A1 WO 2000012067A1 US 9919575 W US9919575 W US 9919575W WO 0012067 A1 WO0012067 A1 WO 0012067A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
agent
base
useful
saccharinate
Prior art date
Application number
PCT/US1999/019575
Other languages
English (en)
Inventor
James W. Rayburn
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to CA002341522A priority Critical patent/CA2341522A1/fr
Priority to AU60211/99A priority patent/AU6021199A/en
Priority to EP99968215A priority patent/EP1107738A4/fr
Priority to JP2000567187A priority patent/JP2003525855A/ja
Publication of WO2000012067A1 publication Critical patent/WO2000012067A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a novel salt form of certain pharmacologically active organic bases and their preparation.
  • the class will be exemplified by the saccharinate salt of buspirone, a useful anti-anxiety agent.
  • the present invention involves stable crystalline saccharinate salts of orally administrable medicinal bases.
  • Saccharin chemically 1 ,2- benzisothiazol-3(2H)-one 1 ,1 , dioxide, is used as a sweetener, most commonly in the form of its sodium salt dihydrate. While it is used as a sweetener in pharmaceutical applications, its use is as a component of a mixture of ingredients.
  • saccharine provides a sweet taste in dilute aqueous solutions where it is about 500 times sweeter than sugar with the sweet taste still detectable in 1 :100,000 dilution; nonetheless saccharin has a bitter, metallic aftertaste. Because saccharin's taste is most pleasant in dilute solution, care must be exercised in formulating saccharin in its solid state because of a very objectionable taste.

Abstract

L'invention concerne un sel de saccharinate de bases organiques médicinales qui ne sont pas des alcaloïdes, et constituant une nouvelle forme saline présentant des propriétés organoleptiques améliorées et une solubilité réduite.
PCT/US1999/019575 1998-08-27 1999-08-26 Nouvelle forme saline pharmaceutique WO2000012067A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002341522A CA2341522A1 (fr) 1998-08-27 1999-08-26 Nouvelle forme saline pharmaceutique
AU60211/99A AU6021199A (en) 1998-08-27 1999-08-26 Novel pharmaceutical salt form
EP99968215A EP1107738A4 (fr) 1998-08-27 1999-08-26 Nouvelle forme saline pharmaceutique
JP2000567187A JP2003525855A (ja) 1998-08-27 1999-08-26 新規な薬剤塩形態

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9815498P 1998-08-27 1998-08-27
US60/098,154 1998-08-27

Publications (1)

Publication Number Publication Date
WO2000012067A1 true WO2000012067A1 (fr) 2000-03-09

Family

ID=22267557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019575 WO2000012067A1 (fr) 1998-08-27 1999-08-26 Nouvelle forme saline pharmaceutique

Country Status (6)

Country Link
EP (1) EP1107738A4 (fr)
JP (1) JP2003525855A (fr)
CN (1) CN1348363A (fr)
AU (1) AU6021199A (fr)
CA (1) CA2341522A1 (fr)
WO (1) WO2000012067A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015682A1 (fr) * 1999-08-31 2001-03-08 Grünenthal GmbH Sels pharmaceutiques de tramadol
EP1136487A1 (fr) * 2000-03-20 2001-09-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Sels de la nicotine, procédé pour leur préparation et leur utilisation comme agents pour la cessation de fumer
WO2002067916A2 (fr) * 2001-02-28 2002-09-06 Grünenthal GmbH Sels pharmaceutiques
US6849623B2 (en) 2001-06-25 2005-02-01 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Xanthine and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use
DE202010001237U1 (de) 2010-01-21 2010-04-01 Grünenthal GmbH Kombination aus Tramadol und Acetaminophen als Brausetablette
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2258357A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
US20110009368A1 (en) * 2007-12-12 2011-01-13 Ultimorphix Technologies B.V. Solid forms of tenofovir disoproxil
EP2275095A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
WO2011063115A1 (fr) 2009-11-19 2011-05-26 Braincells Inc. Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
WO2011091033A1 (fr) 2010-01-20 2011-07-28 Braincells, Inc. Modulation de la neurogenèse par des agents ppar
EP2377530A2 (fr) 2005-10-21 2011-10-19 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
US20160175295A1 (en) * 2013-07-25 2016-06-23 Almirall, S.A. Combinations comprising maba compounds and corticosteroids
US20170137370A1 (en) * 2001-02-28 2017-05-18 Grünenthal GmbH Pharmaceutical salts
US10005771B2 (en) 2014-09-26 2018-06-26 Almirall, S.A. Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
US10300072B2 (en) 2011-11-11 2019-05-28 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
WO2023177294A1 (fr) 2022-03-18 2023-09-21 Plethora Therapeutics B.V. Administration transmucosale de composés psychoactifs

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
CN107868117B (zh) * 2016-09-28 2021-04-23 中国科学院苏州纳米技术与纳米仿生研究所 司坦唑醇糖精盐及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1288002A (fr) * 1954-06-14 1962-03-24 Pfizer & Co C Perfectionnements apportés aux procédés de fabrication de composés d'imidazoline
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES271829A1 (es) * 1960-12-19 1962-03-01 Tanabe Seiyaku Co Un procedimiento para preparar una sal comestible de acido benzofenoma-2-carboxilico y 1-metil-3-(di-2-tienilmetilen) piperidina
US4711784A (en) * 1986-01-07 1987-12-08 Warner-Lambert Company Encapsulation composition for use with chewing gum and edible products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1288002A (fr) * 1954-06-14 1962-03-24 Pfizer & Co C Perfectionnements apportés aux procédés de fabrication de composés d'imidazoline
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1107738A4 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781852B2 (en) * 1999-08-31 2005-06-16 Grunenthal Gmbh Pharmaceutical tramadol salts
WO2001015682A1 (fr) * 1999-08-31 2001-03-08 Grünenthal GmbH Sels pharmaceutiques de tramadol
KR100730502B1 (ko) * 1999-08-31 2007-06-22 그뤼넨탈 게엠베하 약제학적 트라마돌 염 및 이를 함유하는 투여 제형
US6723343B2 (en) 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
EP1136487A1 (fr) * 2000-03-20 2001-09-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Sels de la nicotine, procédé pour leur préparation et leur utilisation comme agents pour la cessation de fumer
CN100352431C (zh) * 2001-02-28 2007-12-05 格吕伦塔尔有限公司 药用盐
JP2004527491A (ja) * 2001-02-28 2004-09-09 グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 薬学的塩
WO2002067916A3 (fr) * 2001-02-28 2003-12-18 Gruenenthal Gmbh Sels pharmaceutiques
WO2002067916A2 (fr) * 2001-02-28 2002-09-06 Grünenthal GmbH Sels pharmaceutiques
US10160719B2 (en) 2001-02-28 2018-12-25 Grunenthal Gmbh Pharmaceutical salts
CZ306998B6 (cs) * 2001-02-28 2017-11-08 Grünenthal GmbH Farmaceutické soli
US20170137370A1 (en) * 2001-02-28 2017-05-18 Grünenthal GmbH Pharmaceutical salts
JP4737583B2 (ja) * 2001-02-28 2011-08-03 グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 薬学的塩
JP2011079843A (ja) * 2001-02-28 2011-04-21 Gruenenthal Gmbh 薬学的塩
US6849623B2 (en) 2001-06-25 2005-02-01 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Xanthine and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use
EP2275095A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258359A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
EP2275096A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258358A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2258357A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
EP2377530A2 (fr) 2005-10-21 2011-10-19 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
EP2382975A2 (fr) 2006-05-09 2011-11-02 Braincells, Inc. Neurogénèse par modulation d'angiotensine
US20110009368A1 (en) * 2007-12-12 2011-01-13 Ultimorphix Technologies B.V. Solid forms of tenofovir disoproxil
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2011063115A1 (fr) 2009-11-19 2011-05-26 Braincells Inc. Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
WO2011091033A1 (fr) 2010-01-20 2011-07-28 Braincells, Inc. Modulation de la neurogenèse par des agents ppar
DE202010001237U1 (de) 2010-01-21 2010-04-01 Grünenthal GmbH Kombination aus Tramadol und Acetaminophen als Brausetablette
US10300072B2 (en) 2011-11-11 2019-05-28 Almirall, S.A. Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
US20160175295A1 (en) * 2013-07-25 2016-06-23 Almirall, S.A. Combinations comprising maba compounds and corticosteroids
US10456390B2 (en) * 2013-07-25 2019-10-29 Almirall, S.A. Combinations comprising MABA compounds and corticosteroids
US10005771B2 (en) 2014-09-26 2018-06-26 Almirall, S.A. Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
WO2023177294A1 (fr) 2022-03-18 2023-09-21 Plethora Therapeutics B.V. Administration transmucosale de composés psychoactifs

Also Published As

Publication number Publication date
CN1348363A (zh) 2002-05-08
JP2003525855A (ja) 2003-09-02
EP1107738A4 (fr) 2003-01-22
CA2341522A1 (fr) 2000-03-09
EP1107738A1 (fr) 2001-06-20
AU6021199A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
WO2000012067A1 (fr) Nouvelle forme saline pharmaceutique
US5811436A (en) Oral liquid compositions containing paroxetine resinate
US6306904B1 (en) Antihistaminic/antitussive compositions
US20030083354A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US6037358A (en) Decongestant/antihistaminic compositions
EP1778183B1 (fr) Compositions liquides de paroxetine
HU204994B (en) Process for producint new ranitidine derivatives and pharmaceutical compositions comprising same
WO2003086357A1 (fr) Compositions liquides et semi solides a base de tannate de diphenhydramine et methodes d'utilisation
US3976787A (en) Pharmaceutical guanidine preparations and methods of using same
US6462094B1 (en) Decongestant/expectorant compositions
JP3465820B2 (ja) トロバフロキサシン経口懸濁剤
EP1747781B1 (fr) Preparation pharmaceutique orale de fosfomycine stable et destinee a des diabetiques
EP0194336A2 (fr) Formulation orale de mobenzoxamine
SK15472001A3 (sk) Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu liečiva použiteľného na liečenie alebo prevenciu porúch nálady, porúch adaptácie alebo stavov úzkosti a depresie
CA2008183C (fr) Composition pharmaceutique liquide pour derives du piperidinealcanol
EP1003557B1 (fr) Sels a proprietes organoleptiques benefiques
MXPA01000867A (en) Novel pharmaceutical salt form
US20040132827A1 (en) Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
US6586469B2 (en) Antihistaminic/antitussive compositions
WO2003086356A1 (fr) Compositions de formes dosifiees solides de tannate de diphenhydramine et procedes d'utilisation associes
US6566396B2 (en) Antitussive/antihistaminic compositions
JPS6350355B2 (fr)
US20030044461A1 (en) Antitussive/expectorant compositions
EP0431759A1 (fr) Procédé de préparation d'absorbate de résine de ranitidine
CA1117528A (fr) Phosphate de glaucine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99810139.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000867

Country of ref document: MX

Ref document number: 2001/00225

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1999968215

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2341522

Country of ref document: CA

Ref document number: 2341522

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 60211/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999968215

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999968215

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI9912435

Country of ref document: BR

Free format text: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL, POR TER SIDO A FASE NACIONAL INTEMPESTIVA.